PE20210662A1 - Activadores de la respuesta a proteinas desplegadas - Google Patents
Activadores de la respuesta a proteinas desplegadasInfo
- Publication number
- PE20210662A1 PE20210662A1 PE2020002206A PE2020002206A PE20210662A1 PE 20210662 A1 PE20210662 A1 PE 20210662A1 PE 2020002206 A PE2020002206 A PE 2020002206A PE 2020002206 A PE2020002206 A PE 2020002206A PE 20210662 A1 PE20210662 A1 PE 20210662A1
- Authority
- PE
- Peru
- Prior art keywords
- halo
- independently
- compound
- orc
- orb
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Referido a un compuesto de formula (I); en donde R1, R2, R3 y R4 son, independientemente, H, halo, -ORA, -SRA, entre otros; A1, A2, A3 y A4 son, independiente, H, halo, o alquilo; G1 es halo, -ORB, -SRB, entre otros; G2 es halo, -ORC, -SRC, entre otros; X y Z son, independientemente, O, S, o -NRD; y RA, RB, RC y RD son, independientemente, H o alquilo; en donde, cuando estan presentes, -ORB y -ORC no son ambos -OH. Un compuesto seleccionado es (S)- o (R)- 3-(4-hidroxifenil)-3-(4-metoxifenil)-7-(trifluorometil)indolin-2-ona. Dichos compuestos inhiben la proliferacion de las celulas cancerosas y destruyen las celulas cancerosas de mama, ovario y endometrio ER alfa positivas, lo que evita la reactivacion de los tumores anos despues. Tambien refiere una composicion farmaceutica que comprende dicho compuesto, siendo util en el tratamiento del cancer ER alfa positivo resistentes a la terapia en comparacion con BHPI y otras terapias convencionales (terapias endocrinas, tamoxifeno y fulvestrant/ICI).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693641P | 2018-07-03 | 2018-07-03 | |
| PCT/US2019/040058 WO2020009958A1 (en) | 2018-07-03 | 2019-07-01 | Activators of the unfolded protein response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210662A1 true PE20210662A1 (es) | 2021-03-31 |
Family
ID=69059783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020002206A PE20210662A1 (es) | 2018-07-03 | 2019-07-01 | Activadores de la respuesta a proteinas desplegadas |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20210276951A1 (es) |
| EP (1) | EP3817741A4 (es) |
| JP (1) | JP2021529757A (es) |
| KR (1) | KR20210027382A (es) |
| CN (1) | CN112423743A (es) |
| AU (1) | AU2019299221A1 (es) |
| BR (1) | BR112020025591A2 (es) |
| CA (1) | CA3103958A1 (es) |
| CL (1) | CL2020003423A1 (es) |
| CO (1) | CO2020016690A2 (es) |
| CR (1) | CR20210060A (es) |
| DO (1) | DOP2020000256A (es) |
| EA (1) | EA202190146A1 (es) |
| EC (1) | ECSP20084330A (es) |
| IL (1) | IL279429A (es) |
| JO (1) | JOP20200344A1 (es) |
| MA (1) | MA53105A (es) |
| MX (1) | MX2021000043A (es) |
| PE (1) | PE20210662A1 (es) |
| PH (1) | PH12020552223A1 (es) |
| SG (1) | SG11202012902WA (es) |
| WO (1) | WO2020009958A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021000043A (es) | 2018-07-03 | 2021-03-25 | Univ Illinois | Activadores de la respuesta a proteinas desplegadas. |
| WO2021222738A1 (en) * | 2020-05-01 | 2021-11-04 | The Board Of Trustees Of The University Of Illinois | Compounds for estrogen receptor positive cancers |
| WO2022020605A1 (en) * | 2020-07-23 | 2022-01-27 | The Board Of Trustees Of The University Of Illinois | Treatment of metastasized estrogen receptor positive breast cancer |
| WO2022032146A1 (en) * | 2020-08-07 | 2022-02-10 | Systems Oncology, Llc | Methods for inhibiting growth of era positive cancers |
| US20230391721A1 (en) * | 2020-10-23 | 2023-12-07 | The Board Of Trustees Of The University Of Illinois | Anticancer compounds selective for er-positive cancers |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006508893A (ja) | 2002-03-15 | 2006-03-16 | イーライ・リリー・アンド・カンパニー | ステロイドホルモン核内レセプターモジュレーターとしてのジヒドロインドール−２−オン誘導体 |
| US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| JP4989976B2 (ja) * | 2004-02-13 | 2012-08-01 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 翻訳開始阻害剤としての３−３−二置換オキシインドール |
| US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| US20070299102A1 (en) * | 2004-04-08 | 2007-12-27 | Topo Target A/S | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer |
| US20070072897A1 (en) | 2005-09-29 | 2007-03-29 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| TW200817382A (en) | 2006-08-24 | 2008-04-16 | Wyeth Corp | Process for preparing indolinone phenylaminopropanol derivatives |
| JP2010512355A (ja) | 2006-12-11 | 2010-04-22 | トポターゲット・アクティーゼルスカブ | 癌の処置のためのジフェニルオキシ−インドール−２−オン化合物のプロドラッグ |
| AU2008240599A1 (en) * | 2007-04-24 | 2008-10-30 | Topotarget A/S | Substituted 3-(4-hydroxyphenyl)-indolin-2-one-compounds |
| EP2520561B1 (en) | 2007-06-08 | 2016-02-10 | MannKind Corporation | IRE-1A Inhibitors |
| WO2010109008A1 (en) | 2009-03-26 | 2010-09-30 | Topotarget A/S | Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones |
| US20160106711A1 (en) | 2012-09-20 | 2016-04-21 | President And Fellows Of Harvard College | 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation |
| US9316631B1 (en) | 2012-10-19 | 2016-04-19 | Whitehead Institute For Biomedical Research | ER-stress inducing compounds and methods of use thereof |
| WO2014113820A1 (en) * | 2013-01-18 | 2014-07-24 | Shapiro David J | Estrogen receptor inhibitors |
| JP6806562B2 (ja) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| EP3004090B1 (en) | 2013-05-28 | 2017-10-25 | Astrazeneca AB | Chemical compounds |
| MX2021000043A (es) | 2018-07-03 | 2021-03-25 | Univ Illinois | Activadores de la respuesta a proteinas desplegadas. |
-
2019
- 2019-07-01 MX MX2021000043A patent/MX2021000043A/es unknown
- 2019-07-01 EP EP19831532.7A patent/EP3817741A4/en not_active Withdrawn
- 2019-07-01 US US17/254,771 patent/US20210276951A1/en active Pending
- 2019-07-01 JP JP2020573046A patent/JP2021529757A/ja active Pending
- 2019-07-01 CR CR20210060A patent/CR20210060A/es unknown
- 2019-07-01 CN CN201980045131.2A patent/CN112423743A/zh active Pending
- 2019-07-01 AU AU2019299221A patent/AU2019299221A1/en not_active Abandoned
- 2019-07-01 BR BR112020025591-2A patent/BR112020025591A2/pt not_active IP Right Cessation
- 2019-07-01 SG SG11202012902WA patent/SG11202012902WA/en unknown
- 2019-07-01 KR KR1020217001833A patent/KR20210027382A/ko unknown
- 2019-07-01 WO PCT/US2019/040058 patent/WO2020009958A1/en active Application Filing
- 2019-07-01 CA CA3103958A patent/CA3103958A1/en not_active Abandoned
- 2019-07-01 EA EA202190146A patent/EA202190146A1/ru unknown
- 2019-07-01 PE PE2020002206A patent/PE20210662A1/es unknown
- 2019-07-01 MA MA053105A patent/MA53105A/fr unknown
- 2019-07-01 JO JOP/2020/0344A patent/JOP20200344A1/ar unknown
-
2020
- 2020-02-26 US US16/801,839 patent/US11046647B2/en active Active
- 2020-12-14 IL IL279429A patent/IL279429A/en unknown
- 2020-12-19 PH PH12020552223A patent/PH12020552223A1/en unknown
- 2020-12-29 EC ECSENADI202084330A patent/ECSP20084330A/es unknown
- 2020-12-29 CL CL2020003423A patent/CL2020003423A1/es unknown
- 2020-12-29 DO DO2020000256A patent/DOP2020000256A/es unknown
- 2020-12-30 CO CONC2020/0016690A patent/CO2020016690A2/es unknown
-
2021
- 2021-05-13 US US17/319,447 patent/US11584718B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL279429A (en) | 2021-01-31 |
| JOP20200344A1 (ar) | 2020-12-31 |
| MX2021000043A (es) | 2021-03-25 |
| CR20210060A (es) | 2021-04-08 |
| AU2019299221A1 (en) | 2021-02-04 |
| US20200190029A1 (en) | 2020-06-18 |
| DOP2020000256A (es) | 2021-03-15 |
| JP2021529757A (ja) | 2021-11-04 |
| US11584718B2 (en) | 2023-02-21 |
| CN112423743A (zh) | 2021-02-26 |
| US20210276951A1 (en) | 2021-09-09 |
| BR112020025591A2 (pt) | 2021-03-23 |
| SG11202012902WA (en) | 2021-01-28 |
| PH12020552223A1 (en) | 2021-06-28 |
| MA53105A (fr) | 2021-05-12 |
| CO2020016690A2 (es) | 2021-01-18 |
| WO2020009958A1 (en) | 2020-01-09 |
| EA202190146A1 (ru) | 2021-04-27 |
| EP3817741A1 (en) | 2021-05-12 |
| US11046647B2 (en) | 2021-06-29 |
| KR20210027382A (ko) | 2021-03-10 |
| CL2020003423A1 (es) | 2021-05-14 |
| EP3817741A4 (en) | 2022-07-06 |
| ECSP20084330A (es) | 2021-01-29 |
| CA3103958A1 (en) | 2020-01-09 |
| US20210340100A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210662A1 (es) | Activadores de la respuesta a proteinas desplegadas | |
| CL2019002032A1 (es) | Procesos para preparar un inhibidor de jak1 (divisional de solicitud 1790-2018). | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| CO2020012824A2 (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma | |
| PE20180520A1 (es) | Compuestos antibacterianos | |
| PE20160208A1 (es) | Compuestos de pirimidinodiona contra estados cardiacos | |
| PE20180455A1 (es) | Compuestos heterociclicos como inhibidores de lsd1 | |
| PE20151939A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| NI201700174A (es) | Derivados de amidas policíclicas como inhibidores de cdk | |
| MA38390B1 (fr) | Composés tétrahydropyrrolothiazines | |
| NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
| GT201000172A (es) | Inhibidores de cinesina como productos terapéuticos para el cáncer | |
| ES2969901T3 (es) | Cocristal de ácido benzoico y compuesto de sulfonamida para el tratamiento de tumores | |
| GT200600394A (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis. | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| BR112015011760A2 (pt) | composto, uso do composto, e uso de uma composição farmacêutica | |
| BR112021017620A2 (pt) | Compostos macrocíclicos | |
| DOP2017000188A (es) | Compuestos de benzoxaborol 4-sustituidos y uso de los mismos | |
| PE20190414A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| BR112017016488A2 (pt) | triazóis substituídos e métodos relacionados aos mesmos | |
| CO2018006928A2 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| PE20170920A1 (es) | Piperidinilpirazolopirimidinonas y utilizacion de las mismas | |
| EA201991595A1 (ru) | Активатор nrf2 |